Safety of iron polymaltose given as a total dose iron infusion

Internal Medicine Journal

Volumn 36, Issue 10, 2006, Pages 672-674

  Newnham, E ^a   Ahmad, I ^a,b   Thornton, A ^c   Gibson, P R ^a,c  

^a BOX HILL HOSPITAL   (Australia)

^b MAROONDAH HOSPITAL   (Australia)

^c FRANKSTON HOSPITAL   (Australia)

Author keywords

Anaphylaxis; Iron deficiency; Premedication; Safety; Total dose iron infusion

Indexed keywords

IRON POLYMALTOSE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CARDIOPULMONARY INSUFFICIENCY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PREMEDICATION; PRIORITY JOURNAL; RASH; SEIZURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; EXANTHEMA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; NAUSEA; RETROSPECTIVE STUDIES;

EID: 33748367449     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01156.x     Document Type: Article

References (18)

1. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive cardiac failure. Eur J Heart Failure 2002; 4: 681-6.
2. Nordyke RJ, Kim JJ, Goldberg GA, Vendiola R, Batra D, McCamish M et al. Impact of anemia on hospitalization time, charges and mortality in patients with heart failure. Value Health 2004; 7: 464-71.
3. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron deficient adolescent girls. Lancet 1996; 348: 992-6.
4. Smieja MJ, Cook DJ, Hunt DL, Ali MA, Guyatt GH. Can Med Assoc J 1996; 155: 691-6.
5. Ahmad I, Gibson PR. Management of iron deficiency in patients admitted to hospital: time for a rethink of treatment principles. Intern Med J 2006; 36: 347-54.
6. Goddard AF, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. Gut 2000; 46 (Suppl. 4): S1-5.
7. Schindler E, Scholz S, Boldt J, Zuckman B, Knothe C, Dietrich G et al. Effectiveness of oral vs parenteral iron substitution in autologous blood donors. Infusionstherapie und Transfusionmedizin 1994; 21: 236-41.
8. Macdougall IC. Strategies for iron supplementation: oral vs. intravenous. Kidney Int 1999; 55 (Suppl. 69): S61-6.
9. De Silva AP, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage tolerance and efficacy. Inflamm Bowel Dis 2003; 9: 316-20.
10. Wingard RL, Parker RA, Ismail N, Halim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-9.
11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anaemia of inflammation. Blood 2003; 102: 783-8.
12. Gasche C. Anaemia in IBD: the overlooked villain? Inflamm - Bowel Dis 2000; 6: 142-50.
13. Aders H. The stain that lasts. United J 2005; Autumn: 19-20.
14. Greenberg G. Sarcoma after intramuscular iron injection. BMJ 1976; 1: 1508-9.
15. Rolla G, Bucca C, Brussino L. Systemic reactions to intravenous iron therapy in patients receiving angiotensin converting enzyme inhibitor. J Allergy Clin Immunol 1994; 93: 1074-5.
16. Anon. Ferrum H injection. In: MIMS Annual. 29th edn. St Leonards, NSW: CMPMedica. 2005; 734-6.
17. Hamstra RD, Block MH, Shockey AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726-31.
18. Silverstein SB, Rodgers GM. Parenteral Iron therapy options. Am J Hematol 2004; 76: 74-8.